OpenLoop Health clinicians retain the decision to prescribe compounded GLP-1s to patients
Tirzepatide: the dual-receptor comparison Tirzepatide adds GIP receptor activation to GLP-1, creating appetite suppression that is faster and stronger than semaglutide alone
Oral GLP1RAs are also beginning to reach clinical practice, and will open up access for those who do not want, or cannot have, injections
However, the timeline varies significantly depending on starting dose, dose escalation speed, and individual tolerance
The primary objective of the trial was to assess the effects of empagliflozin as an adjunct to standard of care therapy, including RAS-inhibitor therapy when appropriate, on time to kidney disease progression or cardiovascular death
KD also shows potential in the prevention and treatment of cardiovascular disease (76)